Rühl Sebastian, Li Zhenrui, Srivastava Shagun, Mari Luigi, Guy Clifford S, Yang Mao, Moldoveanu Tudor, Green Douglas R
Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA.
T3 Pharmaceuticals, Allschwil, Switzerland.
Cell Death Differ. 2025 Feb;32(2):320-336. doi: 10.1038/s41418-024-01386-3. Epub 2024 Oct 15.
BCL-2 family proteins regulate apoptosis by initiating mitochondrial outer membrane permeabilization (MOMP). Activation of the MOMP effectors BAX and BAK is controlled by the interplay of anti-apoptotic BCL-2 proteins (e.g., MCL-1) and pro-apoptotic BH3-only proteins (e.g., BIM). Using a genome-wide CRISPR-dCas9 transactivation screen we identified BNIP5 as an inhibitor of BAK-, but not BAX-induced apoptosis. BNIP5 blocked BAK activation in different cell types and in response to various cytotoxic therapies. The BH3 domain of BNIP5 was both necessary and sufficient to block BAK activation. Mechanistically, the BH3 domain of BNIP5 acts as a selective BAK activator, but a poor de-repressor of complexes between BAK and pro-survival BCL-2 family proteins. By promoting the binding of activated BAK to MCL-1 or BCL-xL, BNIP5 inhibits apoptosis when BAX is absent. Based on our observations, BNIP5 can act functionally as an anti-apoptotic BH3-only protein.
BCL-2家族蛋白通过引发线粒体外膜通透性改变(MOMP)来调节细胞凋亡。MOMP效应蛋白BAX和BAK的激活受抗凋亡BCL-2蛋白(如MCL-1)和促凋亡仅含BH3结构域蛋白(如BIM)相互作用的控制。利用全基因组CRISPR-dCas9反式激活筛选,我们鉴定出BNIP5是BAK诱导凋亡的抑制剂,但不是BAX诱导凋亡的抑制剂。BNIP5在不同细胞类型中以及对各种细胞毒性疗法均能阻断BAK激活。BNIP5的BH3结构域对于阻断BAK激活既必要又充分。从机制上讲,BNIP5的BH3结构域作为选择性BAK激活剂,但却是BAK与促生存BCL-2家族蛋白之间复合物的低效去阻遏物。通过促进活化的BAK与MCL-1或BCL-xL结合,当BAX缺失时BNIP5抑制细胞凋亡。基于我们的观察结果,BNIP5在功能上可作为一种抗凋亡的仅含BH3结构域蛋白。